DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer

Nature Communications

Volumn 9, Issue 1, 2018, Pages

  Luo, Na ^a,b   Nixon, Mellissa J ^b   Gonzalez Ericsson, Paula I ^b,c   Sanchez, Violeta ^b,c   Opalenik, Susan R ^b   Li, Huili ^d   Zahnow, Cynthia A ^e   Nickels, Michael L ^b   Liu, Fei ^b   Tantawy, Mohammed N ^b   Sanders, Melinda E ^b,c   Manning, H Charles ^b,f   Balko, Justin M ^b,c  

^a NANKAI UNIVERSITY   (China)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PENN STATE HEALTH CHILDREN S HOSPITAL   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CD8 ANTIGEN; DNA (CYTOSINE 5) METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE; ENTINOSTAT; GAMMA INTERFERON; GUADECITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 9G2; PROGRAMMED DEATH 1 LIGAND 1; STAT1 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DNMT1 PROTEIN, HUMAN;

CELL; DNA; ENZYME; GENE; GENE EXPRESSION; INDUCED RESPONSE; INHIBITION; MAJOR HISTOCOMPATIBILITY COMPLEX; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BT-474 CELL LINE; BT-549 CELL LINE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA METHYLATION; ENZYME INHIBITION; EPIGENETICS; FEMALE; GENE EXPRESSION REGULATION; HCC1395 CELL LINE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; MCF-7 CELL LINE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PROMOTER REGION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR VOLUME; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; DRUG EFFECTS; EXPERIMENTAL MAMMARY NEOPLASM; GENE; GENETICS; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

MURINAE;

ANIMALS; ANTINEOPLASTIC AGENTS; AZACITIDINE; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MHC CLASS I; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; PROMOTER REGIONS, GENETIC; T-LYMPHOCYTES, CYTOTOXIC;

EID: 85040828430     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-02630-w     Document Type: Article

References (27)

1. Emens, L. A. et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC). Presented at the American Association for Cancer Research Annual Meeting; Philadelphia. Abstr. 2859 (2015).
2. Rugo, H. et al. Abstract S5-07: preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1-positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028. Cancer Res. 76, S5-07-S05-07 (2016).
3. Loi, S. et al. RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin. Cancer Res. 22, 1499-1509 (2016).
4. Ebert, P. J. et al. MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity 44, 609-621 (2016).
5. Bendell, J. C. et al. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). ASCO Meet. Abstr. 34, 3502 (2016).
6. Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160,48-61 (2015).
7. Wang, X. et al. Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Res. 77, 839-850 (2017).
8. Zhou, F. Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation. Int. Rev. Immunol. 28, 239-260 (2009).
9. Shin, D. S. et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 7, 188-201 (2017).
10. Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Eng. J. Med. 375, 819-829 (2016).
11. Li, H. et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 5, 587-598 (2014).
12. Tsai, H. C. et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21, 430-446 (2012).
13. Wrangle, J. et al. Alterations of immune response of non-small cell lung cancer with Azacytidine. Oncotarget 4, 2067-2079 (2013).
14. Wolff, F., Leisch, M., Greil, R., Risch, A. & Pleyer, L. The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation. Cell. Commun. Signal. 15, 13 (2017).
15. Sigalotti, L., Fratta, E., Coral, S. & Maio, M. Epigenetic drugs as immunomodulators for combination therapies in solid tumors. Pharmacol. Ther. 142, 339-350 (2014).
16. Chiappinelli, K. B. et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162, 974-986 (2015).
17. Roulois, D. et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162, 961-973 (2015).
18. Desrichard, A., Snyder, A. & Chan, T. A. Cancer neoantigens and applications for immunotherapy. Clin. Cancer. Res. 22, 807-812 (2016).
19. Lu, Y. C. & Robbins, P. F. Cancer immunotherapy targeting neoantigens. Semin. Immunol. 28,22-27 (2016).
20. Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348,69-74 (2015).
21. TCGA. Comprehensive molecular portraits of human breast tumours. Nature 490,61-70 (2012).
22. Yang, H. et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 28, 1280-1288 (2014).
23. Ercolini, A. M. et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J. Exp. Med. 201 , 1591-1602 (2005).
24. Clement, M. et al. Anti-CD8 antibodies can trigger CD8+ T cell effector function in the absence of TCR engagement and improve peptide-MHCI tetramer staining. J. Immunol. 187, 654-663 (2011).
25. Burke, J. R. et al. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J. Biol. Chem. 278, 1450-1456 (2003).
26. Peng, D. et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527, 249-253 (2015).
27. Acevedo, M. et al. A CDK4/6-dependent epigenetic mechanism protects cancer cells from PML-induced senescence. Cancer Res. 76, 3252-3264 (2016).